4.8 Article

Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma

期刊

ONCOGENE
卷 40, 期 18, 页码 3273-3286

出版社

SPRINGERNATURE
DOI: 10.1038/s41388-021-01761-1

关键词

-

资金

  1. National Institutes of Health [R01-NS113352, R01CA77816, R01-CA121192]
  2. Department of Veterans Affairs [I01-CX000916]

向作者/读者索取更多资源

SLFN5 is overexpressed in human pancreatic ductal adenocarcinoma (PDAC) and correlates with worse outcomes, targeted deletion of SLFN5 can inhibit PDAC cell proliferation and tumorigenesis, it promotes transcription of key genes that stimulate S phase progression by binding/blocking E2F7.
We provide evidence that a member of the human Schlafen (SLFN) family of proteins, SLFN5, is overexpressed in human pancreatic ductal adenocarcinoma (PDAC). Targeted deletion of SLFN5 results in decreased PDAC cell proliferation and suppresses PDAC tumorigenesis in in vivo PDAC models. Importantly, high expression levels of SLFN5 correlate with worse outcomes in PDAC patients, implicating SLFN5 in the pathophysiology of PDAC that leads to poor outcomes. Our studies establish novel regulatory effects of SLFN5 on cell cycle progression through binding/blocking of the transcriptional repressor E2F7, promoting transcription of key genes that stimulate S phase progression. Together, our studies suggest an essential role for SLFN5 in PDAC and support the potential for developing new therapeutic approaches for the treatment of pancreatic cancer through SLFN5 targeting.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据